Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Frid | M | 52 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
Arthur T. Healey | M | 63 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 3 years |
Alex Shlyankevich | M | 63 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 7 years |
Yuriy Gankin | M | 58 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
Douglas Moore | M | 67 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 2 years |
Marc Duey | M | 68 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 10 years |
Michael Kody | M | - |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Valeria Povolotsky | M | - |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 8 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Maria Vilenchik
- Personal Network